---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-008200"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T22:54:02.514213+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MyMD Pharmaceuticals announces positive preclinical data for MYMD-1 in RA model

## Summary
- MYMD-1 reduced histopathological changes vs placebo (p<0.0001 composite score) in RA model.
- Disease severity reduced 47% with MYMD-1 450 mg/kg/day orally vs 37% for etanercept.
- Oral TNF-α inhibitor shows potential to disrupt current market; early-stage RA trials planned.
- Data presented at 2023 Society of Toxicology Annual Meeting on March 20, 2023.

## SEC filing metadata
- accession: 0001493152-23-008200
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223008200/0001493152-23-008200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223008200/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-008200
- JSON: https://secwatch.observer/filing/0001493152-23-008200.json
- Plain text: https://secwatch.observer/filing/0001493152-23-008200.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.